

Andreas Schreiner, MD

Dr Andreas Schreiner is a certified psychiatrist and neurologist who currently holds the position of Vice President Medical & Scientific Affairs CNS and Internal Medicine at Janssen-Cilag Europe, Middle East and Africa.



Dr Schreiner studied medicine at the Universities of Heidelberg and Mannheim, Germany, and completed residencies in the Department of Neurology at the University Hospital in Mannheim and in Psychiatry at the Central Institute of Mental Health Mannheim, University of Heidelberg. He joined Janssen-Cilag Medical & Scientific Affairs in 1999.

Dr Schreiner is frequently lecturing and has given more than 500 scientific presentations at national and international meetings. He has also published more than 50 peer-reviewed manuscripts in national and international journals, has written several book chapters and has presented more than 300 abstracts at national and international meetings. Dr Schreiner is a member of many scientific associations including the Schizophrenia International Research Society (SIRS), the German Society of Psychiatry, Psychotherapy and Neurology (DGPPN) the American Academy of Neurology (AAN) and the American Epilepsy Society (AES).

Selected publications:

1. Lambert M, De Marinis T, Pfeil J, Naber D, **Schreiner A**. Establishing remission and good clinical functioning in schizophrenia: Predictors of best outcome with long-term risperidone long-acting injectable treatment. *European Psychiatry* (2009), doi:10.1016/j.eurpsych2009.09.001
2. Kluger G, Schauble B, Rettig K, **Schreiner A**, Holthausen H. Effectiveness of low dose of topiramate following rapid titration in multiply handicapped children and difficult-to-treat epilepsy. *Neuropediatrics* 2009; 40: 61-65
3. **Schreiner A**, Stollhoff K, Ossig W, Unkelbach S, Luer W, Bogdanow M, Schauble B. Conversion from valproic acid onto topiramate in adolescents and adults with epilepsy. *Acta Neurol.Scand.* 2009; 119: 304-312
4. Canuso CM, Youssef EA, Bossie CA, Turkoz I, **Schreiner A**, Simpson GM. Paliperidone extended-release tablets in schizophrenia patients previously treated with risperidone. *Int.Clin.Psychopharmacol.* 2008; 23: 209-215
5. Stefan H, Hubbertz L, Peglau I, Berrouschot J, Kasper B, **Schreiner A**, Krimmer J, Schauble B. Epilepsy outcomes in elderly treated with topiramate. *Acta Neurol.Scand.* 2008; 118: 164-174
6. Forsthoff A, Grunze H, Seemuller F, Stampfer R, Dittmann S, Amann B, Schmidt F, Schafer M, Hermle L, Walden J, **Schreiner A**. Risperidone monotherapy in manic inpatients: an open label, multicentre trial. *World J.Biol.Psychiatry* 2007; 8: 256-261
7. Korinthenberg R, **Schreiner A**. Topiramate in children with west syndrome: a retrospective multicenter evaluation of 100 patients. *J.Child Neurol.* 2007; 22: 302-306
8. Naber D, Greenspan A, **Schreiner A**. Efficacy and safety of risperidone in the treatment of elderly patients suffering from organic brain disease (organic brain syndrome): results from a double-blind, randomized, placebo-controlled clinical trial. *Psychopharmacology (Berl)* 2007; 191: 1027-1029

9. Raedler TJ, **Schreiner A**, Naber D, Wiedemann K. Early onset of treatment effects with oral risperidone. *BMC.Psychiatry* 2007; 7: 4-
10. Normann C, Schmauss M, Bakri N, Gerwe M, **Schreiner A**. Initial treatment of severe acute psychosis with fast orally disintegrating risperidone tablets. *Pharmacopsychiatry* 2006; 39: 209-212
11. Raedler TJ, **Schreiner A**, Naber D, Wiedemann K. Gender-specific effects in the treatment of acute schizophrenia with risperidone. *Pharmacopsychiatry* 2006; 39: 171-174
12. Heger S, Trott GE, Meusers M, Schulz E, Rothenberger A, Rettig K, Medori R, **Schreiner A**, Remschmidt H. [Switching from a short-acting to a long-acting methylphenidate preparation: a multicentre, open study in children with ADHD]. *Z.Kinder Jugendpsychiatr.Psychother.* 2006; 34: 257-265
13. Glick ID, Shkedy Z, **Schreiner A**. Differential early onset of therapeutic response with risperidone vs conventional antipsychotics in patients with chronic schizophrenia. *Int.Clin.Psychopharmacol.* 2006; 21: 261-266
14. **Schreiner A**. Treatment of bipolar mania with risperidone. *Psychiatr.Prax.* 2006; 33 Suppl 1: S12-S17
15. Hewer W, **Schreiner A**. Psychiatrische Notfälle [Emergencies in Psychiatry] Kursbuch Notfallmedizin. Deutscher Ärzteverlag 2006; 26:392-414
16. Stoppe G, **Schreiner A**, Schmitt AB. Changeover to risperidone after treatment with conventional low potency neuroleptics in dementia patients. An observation study during usage. *Dtsch Med Wochensch.* 2006; Mar 3; 131 (9): 423-9
17. Mohl A, Westlye K, Opjordsmoen S, Lex A, **Schreiner A**, Benoit M, Braunig P, Medori R. Long-acting risperidone in stable patients with schizoaffective disorder. *J.Psychopharmacol.* 2005; 19: 22-31
18. Grosej J, Guerrini R, van OJ, Lahaye M, **Schreiner A**, Schwalen S. Experience with topiramate monotherapy in elderly patients with recent-onset epilepsy. *Acta Neurol.Scand.* 2005; 112: 144-150
19. Haffmanns PMJ, Oolders HJ, Hoencamp E, **Schreiner A**. Sleep quality in schizophrenia and the effects of atypical antipsychotic medication. *Acta Neuropsychiatrica* 2005; 16(6):281-289
20. Pajonk FG, **Schreiner A**, Peters S, Rettig K, Degner D, Ruther E. Risperidone: an open-label, observational study of the efficacy, tolerability, and prescribing behavior in acutely exacerbated patients with schizophrenia. *J.Clin.Psychopharmacol.* 2005; 25: 293-300
21. Lejeune J, Larmo I, Chrzanowski W, Witte R, Karavatos A, **Schreiner A**, Lex A, Medori R. Oral risperidone plus oral lorazepam versus standard care with intramuscular conventional neuroleptics in the initial phase of treating individuals with acute psychosis. *Int.Clin.Psychopharmacol.* 2004; 19: 259-269
22. Raedler TJ, **Schreiner A**, Naber D, Wiedemann K. Risperidone in the treatment of acute schizophrenia. *J.Clin.Psychopharmacol.* 2004; 24: 335-338
23. **Schreiner A**, Pohlmann-Eden B. Value of the early electroencephalogram after a first unprovoked seizure. *Clin.Electroencephalogr.* 2003; 34: 140-144
24. Jatzko A, Ries S, **Schreiner A**, Braus DF. [Acute tongue and pharyngeal spasms during changeover from clozapine to amisulpride. A case example]. *Nervenarzt* 2000; 71: 919-922
25. **Schreiner A**, Waldherr R, Rohmeiss P, Hewer W. Focal segmental glomerulosclerosis and lithium treatment. *Am J Psychiatry* 2000; 157: 834
26. **Schreiner A**, Hewer W. Is clozapine useful in schizophrenic patients with concomitant chronic inflammatory disease? *Pharmacopsychiatry* (2000); 33:153-4
27. **Schreiner A**, Pohlmann-Eden B. Cerebral hypoxia after cardiopulmonary resuscitation. *Lancet* 1999; 353: 750-751
28. Pohlmann-Eden B, **Schreiner A**. Epileptology of the first-seizure presentation. *Lancet* 1998; 352: 1855-1856
29. Fassbender K, Schmidt R, **Schreiner A**, Fatar M, Muhlhauser F, Daffertshofer M, Hennerici M. Leakage of brain-originated proteins in peripheral blood: temporal profile and diagnostic value in early ischemic stroke. *J.Neurol.Sci.* 1997; 148: 101-105
30. **Schreiner A**, Pohlmann-Eden B, Schwartz A, Hennerici M. Epileptic seizures in subcortical vascular encephalopathy. *J.Neurol.Sci.* 1995; 130: 171-177
31. Rother J, **Schreiner A**, Wentz KU, Hennerici M. Hypoglycemia presenting as basilar artery thrombosis. *Stroke* 1992; 23: 112-113